Award
National Cancer Institute 5R01CA281962-02
The Role and Therapeutic Targeting of GPR56 in Colorectal Cancer
Recipient
University of Texas Health Science Center Houston, Houston, TX
Award Amount
$406,611.00
Ceiling
$406,611.00
Awarded
April 21, 2026
Identifier
5R01CA281962-02
Research project focused on understanding and targeting GPR56 in colorectal cancer to develop improved therapies using antibody-drug conjugates.
Description
This project aims to elucidate the function of GPR56, a novel drug target, in metastasis and develop antibody-drug conjugates (ADCs) for improved therapies. The study will use patient-derived organoids, develop potent GPR56 ADCs, and evaluate their efficacy in preclinical models, including combination therapies to overcome resistance and metastasis.